Potential prognostic biomarker to predict disease progression in in surgically treated mesothelioma patients
Carefully selected patients benefit from cytoreductive surgery and adjuvant chemotherapy for epitheloid pleural mesothelioma, but there is no established biomarker to predict tumor recurrence or progression during the course of the disease. In this work it was shown that the combination of the protein calretinin, MALAT1 and GAS5 could be a potential biomarker for the prediction of tumor recurrence.
Further Information